End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.18 CNY | +0.97% | +2.17% | +2.57% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.57% | 1.81B | C+ | ||
+21.09% | 43.27B | B- | ||
+25.39% | 22.92B | B+ | ||
+19.22% | 15.43B | - | ||
+13.51% | 12.95B | B+ | ||
+44.01% | 11.83B | B | ||
-6.70% | 6.91B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.26% | 5.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600572 Stock
- Ratings Zhejiang CONBA Pharmaceutical Co.,Ltd.